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Abstract
TL1A is a member of the TNF superfamily and its expression is increased in the mucosa of inflammatory bowel disease
patients. Moreover, a subset of Crohn’s disease (CD) patients with the risk TL1A haplotype is associated with elevated TL1A
expression and a more severe disease course. To investigate the in vivo role of elevated TL1A expression, we generated two
transgenic (Tg) murine models with constitutive Tl1a expression in either lymphoid or myeloid cells. Compared to wildtype
(WT) mice, constitutive expression of Tl1a in either lymphoid or myeloid cells showed mild patchy inflammation in the small
intestine, which was more prominent in the ileum. In addition, mice with constitutive Tl1a expression exhibited enhanced
intestinal and colonic fibrosis compared to WT littermates. The percentage of T cells expressing the gut homing chemokine
receptors CCR9 and CCR10 was higher in the Tl1a Tg mice compared to WT littermates. Sustained expression of Tl1A in T
cells also lead to increased Foxp3+ Treg cells. T cells or antigen presenting cells (APC) with constitutive expression of Tl1a
were found to have a more activated phenotype and mucosal mononuclear cells exhibit enhanced Th1 cytokine activity.
These results indicated an important role of TL1A in mucosal T cells and APC function and showed that up-regulation of
TL1A expression can promote mucosal inflammation and gut fibrosis.
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Introduction
Inflammatory bowel disease (IBD), encompassing CD and
ulcerative colitis (UC), is a chronic inflammatory disorder caused
by dysregulated immune responses in a genetically predisposed
individual (reviewed in [1]). CD is a chronic inflammatory
condition that predominately affects the gut with distinctive
pathological features such as patchy transmural intestinal
inflammation, relative sparing of inflammation in the rectum,
intestinal fibrostenosis and a dysregulated T helper (Th) 1 and
Th17 immune response [1,2]. Accumulating data, including
genome-wide association studies (GWAS), demonstrate that more
than 80 distinct genetic loci confer CD susceptibility, and are
being used to define critical molecules and pathways that converge
in physiologic processes that lead to mucosal inflammation [2,3].
Among the several recently discovered IBD associated gene
variants, only those in the tumor necrosis factor superfamily
member 15 (TNFSF15) have been shown to be associated with CD
in all ethnic and age groups [1].
TL1A plays an important role in modulating the adaptive
immune response. In the Th1 effector immune response, binding of
TL1A to its receptor (death domain receptor 3, DR3, TNFRSF25)
enhances IFN-c production from peripheral and mucosal T cells
[4,5]. Studies have shown that TL1A can be induced in APC by
FccR signaling [6,7] and microbial antigen/organisms [8] suggest-
ing that augmentation of the Th1 immune response by TL1A may
occurthroughAPC-Tcellinteractions.Inmurine models ofchronic
mucosal inflammation, TL1A enhanced Th1 and Th17 effector
function by up-regulating IFN-c and IL17 production, respectively,
in gut-associated lymphoid tissue (GALT) CD4
+ cells under Th1/
Th17 polarizing conditions, indicating that TL1A is an important
modulator in the development of gut mucosal inflammation [9]. In
addition to mediating Th1 responses, TL1A also promotes Th2 and
Th17 effector cell function [10,11,12].
Several studies implicate the TL1A/DR3 signaling pathway in
mucosal inflammation. The expression of TL1A and DR3 is up-
regulated in the inflamed gut mucosa of two distinct murine
models of ileal inflammation [13]. Neutralizing anti-mouse TL1A
Ab attenuated inflammation in both the dextran sulfate sodium
induced chronic colitis and a G protein ai2-/- (Gai2
2/2) T cell
transfer colitis model [9]. In humans, TL1A can enhance IFN-c
production in CD4
+ T cells expressing the gut-homing receptor
CCR9 [14]. Increased expression of both TL1A and DR3 was
found in gut mucosal biopsies and lamina propria (LP) T cells of
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16090both UC and CD patients [4,15]. Furthermore, TL1A and DR3
expression are correlated with severity of gut mucosal inflamma-
tion as their transcripts were several times more abundant in RNA
from mucosal biopsies taken from inflamed CD lesions than in
those taken from uninvolved areas [4,15].
To determine the in vivo consequence of increased TL1A
expression, we generated two Tg murine models that constitutively
express Tl1A in either lymphoid or myeloid cells. We found that
constitutive expression of Tl1A in either lymphoid or myeloid cells
induced mild spontaneous patchy intestinal inflammation by 10
months of age. We showed that a higher percentage of T cells and
APC from the mesenteric lymph nodes (MLN) have an activated
phenotype and express the gut homing chemokine receptors
CCR9 and CCR10, associated with increased production of IFN-
c. Consistent with previous reports [16,17], we observed goblet
cell hyperplasia and an increased number of Paneth cells in the
ileum of Tl1a transgenic (Tg) mice. We also showed enhanced
intestinal and colonic fibrosis in mice that constitutively express
Tl1a. These 2 novel murine Tl1A Tg models have patterns of site
directed mucosal inflammation and fibrosis seen in human CD
and may be useful models to study the pathogenesis of IBD.
Results
Generation of in vivo constitutive Tl1a expression in the
myeloid and T cell lineage
To investigate the contribution of sustained APC or T cell Tl1a
expression on gut mucosal homeostasis and inflammation, we
generated Tg mice that constitutively express Tl1a in either T cells
or myeloid cells. We used the proximal lck promoter and CD2
enhancer to drive T cell lineage-specific expression and the c-fms
promoter to mediate myeloid specific expression in APC such as
macrophages and DC [18,19]. We also cloned an IRES-GFP
element downstream of the murine Tl1a so that Tg Tl1a
expressing cells could be identified by GFP. The cloning strategies
and schematic of the Tg construct are described in Materials and
Methods section and figure 1A, respectively. The Tg constructs
were injected into C57BL/6 pronuclei to ensure genetic
homogeneity except for the Tl1a transgene.
Expression of the transgene was determined in myeloid Tg mice
(named FMS-Tl1a-GFP Tg) and T-cell lineage specific expression
of Tl1a (named LCK-CD2-Tl1a-GFP Tg) by the expression of GFP.
We found that in the FMS-Tl1a-GFP Tg mice, GFP was present in
over 70% of CD11c and F4/80 positive cells, and the expression
of the Tl1a transgene persisted as the mice aged (Fig. 1B). The
specificity of the c-fms promoter was illustrated by the fact that we
did not detect GFP expression in CD3, CD4 or CD8 positive T
cells (Fig. 1C). In the LCK-CD2-Tl1A-GFP Tg mice, GFP was
present in over 90% of CD3, CD4 and CD8 positive cells (Fig. 1C).
Similar to the FMS-Tl1a-GFP Tg, the expression of the transgene
in the lymphoid Tl1a Tg mice also persisted as the mice got older
(Fig. 1C). Less than 10% GFP expression was detected in F4/80 or
CD11c positive cells (Fig. 1B), indicating that the Lck promoter
and Cd2 enhancer element drives T cell lineage-specific expres-
sion. We directly showed that Tl1a mRNA is higher in the spleen,
mesenteric lymph nodes (MLN), colon and ileum of both Tg mice
compared to WT mice (Fig. 1D). Together, these data demon-
strate that we generated tissue specific constitutive in vivo
expression of Tl1a in APC and T cells.
Mice with constitutive Tl1a expression do not develop
gross tissue inflammation
Both FMS-Tl1a-GFP and LCK-CD2-Tl1a-GFP Tg mice are
fertile, but are born at less than Mendelian frequency. Mendelian
expectation is 50% transmission of the transgene. When Tg
hemizygous mice are mated to WT mice, the frequency of FMS-
Tl1a-GFP Tg mice born is 42% (58/138) and in LCK-CD2-Tl1aTg
mice, the frequency is 40% (51/126). Both the FMS and LCK Tl1a
Tg mice appeared healthy and gained weight at similar rates
(Fig. 2A). There were no differences in the disease activity index
(DAI) [20] between Tg and WT for up to 10 months (Fig. 2B). We
also did not observe differences in the splenic cell number, MLN
cell number, lamina propria mononuclear cell (LPMC) number in
the small bowel or colon, colon length, small bowel (SB) length or
spleen size between WT and Tl1a Tg mice at 2 or 10 months
(Fig. 2C and data not shown). There was a trend toward higher
cell numbers in the MLN and SB LPMC in Tl1a Tg mice but they
did not reach statistical significance (Fig. 2B and data not shown).
Tl1a expression in APC and T cells induce mild histologic
small bowel inflammation
Elevated Tl1a expression is implicated in gut mucosal
inflammation. We therefore investigated whether mice with
elevated Tl1a expression develop spontaneous colitis at 2 months
and 10 months of age. The colon and small intestine did not show
gross inflammation between WT and Tg mice using a standard
macroscopic scoring system (Fig. 3A) [21]. Another measure for
gut inflammation is to determine myeloperoxidase (MPO) activity
[22]. We found significantly increased MPO activity in the small
intestine of LCK-CD2-Tl1a Tg mice than WT mice (Fig. 3B). MPO
activity was similar in the colon of WT and Tl1a Tg mice (Fig. 3B).
Histological examination of the colon did not reveal increased
inflammatory infiltrates, mucin depletion, epithelial cell hyperpla-
sia, abnormal crypt artchitecture, crypt abscess or erosions in
either WT or Tg mice at 2 or 10 months of age (Fig. 3C and data
not shown). As elevated TL1A production in IBD patients is
associated with fibrostenotic disease [23,24], we assessed whether
the Tl1a Tg mice had increased histologic fibrosis. Notably, we
observed increased fibrosis in the colonic mucosa and submucosa
of both LCK-CD2- and FMS-Tl1a Tg mice as compared to WT
littermate mice by 10 months of age using the Masson Trichrome
stain (Fig. 3D).
At 2 months of age, histological examination of the small
intestine revealed a significant increase in the number of goblet
cells and Paneth cells (Fig. 4A and 4B). There was blunting of the
villi and increased LPMC in the ileum of both the LCK-CD2- and
FMS-Tl1a Tg mice compared to WT mice (Fig. 4A). These
histological changes were reflected by a significant increase in the
inflammatory score in the ileum of Tl1a Tg mice using a standard
quantitative scoring system (Fig. 4B) [21]. We did not observe
villus blunting nor increased mononuclear cells in the LP of the
duodenum and jejunum between WT and Tl1a Tg mice at 2
months of age (Fig. 4A).
At 10 months, we similarly observed Paneth cell hyperplasia in
both LCK-CD2- and FMS-Tl1a Tg compared to WT mice (Fig. 5A
and 5B). In contrast to younger mice (2 months of age), there were
no detectable differences in the number of goblet cells between
WT and Tg mice at 10 months of age (Fig. 5A and 5B). The
inflammatory changes in the small intestine such as increased
mononuclear cell infiltrate of the LP and blunting of the villi was
more prominent and progressive, involving the duodenum,
jejunum and ileum (Fig. 5A and 5B). The increased inflammation
in both LCK-CD2- and FMS-Tl1a Tg mice was associated with
increased histologic fibrosis by the more extensive Masson
Trichrome stain in the small intestine (Fig. 6). Together, these
results indicated that constitutive expression of Tl1a in T cells and
myeloid cells lead to progressive spontaneous intestinal inflamma-
tion and fibrosis.
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PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e16090Mice with constitutive Tl1a expression develop
extra-intestinal pathology
At a low frequency, we observed extra-intestinal pathology in
both the FMS-Tl1a- and LCK-CD2-Tl1a Tg mice. One such feature
was an erythematous ulcerated skin lesion that was observed in 1
out of 58 FMS-Tl1a Tg, 2 of 51 LCK-CD2-Tl1a Tg and 1 out of 155
WT littermate mice (Fig. 7). Another observed pathology was joint
erythema and swelling (Fig. 7) that caused movement difficulties
and resultd in mice not able to feed. Arthropathy was observed in
2 out of 58 FMS Tg, 2 out of 51 LCK-CD2 Tl1a Tg mice and 0 out
of 155 WT mice. Three out of 4 Tg mice with arthropathy had
monoarticular and 1 LCK-CD2-Tl1a Tg mice had polyarticular
Figure 1. Generation of constitutive in vivo expression of Tl1a in T- and antigen presenting cells. (A) Schematic of LCK-CD2-Tl1a and FMS-
Tl1a transgenic construct. An internal ribosomal entry site (IRES) element is used for both transgenic constructs so that a bi-cistronic message can be
made from the transgene and the Tl1a expressing cells are tagged by GFP. (B) Flow cytometric analysis of the transgene marker GFP on either CD11c
or F4/80 gated splenocytes from WT (black filled), LCK-CD2-Tl1a Tg mice (L-Tg, dotted line) or FMS-Tl1a Tg mice (M-Tg, solid grey line). Representative
histograms are shown. (C) Representative analysis of the transgene marker GFP on either CD3, CD4 or CD8 gated splenocytes from WT (black filled),
LCK-CD2-Tl1a Tg mice (L-Tg, dotted line) or FMS-Tl1a Tg mice (solid grey line). (D) Tl1a mRNA expression was determined in the spleen, MLN, ileum or
colon by real-time polymerase chain reaction. Data are expressed as mean percent of b-actin 6 standard deviation (SD). *P,0.05, **P,0.01. n=6
independent littermate mice per group were used for B-D.
doi:10.1371/journal.pone.0016090.g001
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constitutive expression of Tl1a in APC and T cells develop extra-
intestinal pathology such as ulcerated skin lesion and arthropathy.
Accelerated T- and antigen presenting cell activation in
LCK-CD2- and FMS-Tl1a Tg mice
To assess whether constitutively expressed Tl1a can co-
stimulate T cells in vivo, we compared the expression of an
activation marker on CD4
+ and CD8




+ Treg cells were gated
out in order to examine the expression of activation markers on
conventional T cells. At 2 months, there were almost 2 fold higher
CD4
+CD44
+ T cells from the spleen but not MLN of LCK-CD2-
Tl1a Tg mice (Fig. 8A). There was also no difference in the
expression of the activation marker CD44 on CD8
+ T cells in the
MLN and spleen at 2 months of age between Tl1a Tg mice and
WT littermates (Fig. 8A). By 10 months of age, a higher
percentage of Tl1a Tg CD4
+ cells in both the spleen and MLN
expressed the activation marker CD44, particularly in the LCK-
CD2-Tl1a Tg mice (Fig. 8B). In contrast, only CD8
+ cells from the
LCK-CD2-Tl1a Tg (not FMS-Tl1a Tg) spleen and MLN exhibited
an increased expression of the activation marker CD44 (Fig. 8B).
To assess the effect of constitutive Tl1a expression on the
activation state of DC and macrophages, the expression of the
Figure 2. Phenotypic characterization of Tl1a Tg mice. (A) Body weights for WT (grey circle), LCK-CD2-Tl1a Tg mice (L-Tg, black filled triangle) or
FMS-Tl1a Tg mice (M-Tg, black filled square) are shown n=20 per group. Data are expressed as mean weight in grams (g) 6 SD. (B) Stool consistency
(top panels) and fecal blood (bottom panels) were determined using standard methods from WT, LCK-CD2-Tl1a Tg (L-Tg)o rFMS-Tl1a Tg mice (M-Tg)
mice [20]. Data are expressed as mean 6 SD. N=20 per group. (C) Total number of cells were isolated from spleen, MLN and lamina propria
mononuclear cells (LPMC) from the colon and distal 10 cm of small intestine isolated from 10 months old WT (grey circle), LCK-CD2-Tl1a Tg (L-Tg, black
triangle) or FMS-Tl1a Tg mice (M-Tg, open square) and represented as absolute cell number x 10
6. Each data point represents an independent mouse.
doi:10.1371/journal.pone.0016090.g002
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littermate controls. Flow cytometric (FACS) analysis revealed
increased CD86
+ expression on DC (CD11c+) and macrophages
(F4/80+) in both the spleen and MLN of Tl1a Tg mice compared
to WT mice (Fig. 9A). In contrast to LCK-CD2-Tl1a Tg mice, there
was a negligible further increase in the percentage of activated DC
and macrophages over time (compare 2 and 10 months, Fig. 9A
and B). These data demonstrated that sustained Tl1a expression




Constitutive in vivo Tl1a expression leads to an increased
number of T cells expressing Treg and gut homing
markers







+ cells in the
spleen and MLN between FMS-Tl1a Tg, LCK-CD2-Tl1a Tg or WT
littermate mice (data not shown). There was an increase in the
frequency of Foxp3 positive cells in the spleen and MLN of LCK-
CD2-Tl1a Tg mice (Fig. 10A and B). The percentage of Foxp3
+
cells further increased as the LCK-CD2-Tl1a Tg mice aged (Fig. 10A
and B). In contrast, there was no difference in the frequency of
Foxp3
+ cells in the spleen or MLN of FMS-Tl1a Tg mice at both 2
and 10 months (Fig. 10A and B).
A trend toward a higher cell number in the MLN and small
bowel LPMC was noted in older (Fig. 2C and 5A). To determine
whether this finding was due to increased trafficking to the gut
immune compartment, we assessed the expression of the gut
homing markers CCR9 and CCR10 in the MLN and spleen of
Tl1a Tg and WT littermate mice. In the spleen, there was no
difference in CCR9
+ or CCR10
+ cells at 2 or 10 months between
either Tl1a Tg or WT mice (data not shown). Notably, we found
an increase in the percentage of cells expressing CCR9 and
CCR10 in the MLN of LCK-CD2-Tl1a Tg mice compared to WT
Figure 3. Tl1a Tg mice do not develop gross intestinal inflammation but exhibit enhanced colonic fibrosis. (A) Gross appearance (wall
thickening, hyperemia, rigidity or adhesions) of small intestine and colon are measured from 10 months old WT, LCK-CD2-Tl1a Tg (L-Tg)o rFMS-Tl1a Tg
(M-Tg) mice using a standard scoring system [21]. Data are expressed as mean 6 SD. (B) Myeloperoxidase (MPO) activity is measured on the distal
3 cm of ilea and mid-colon and data are expressed as arbitrary unit (U) per gram (g) of protein. *P,0.05 (C) Representative hematoxylin and eosin
(H&E) stained colon section obtained from mid-colon of 10 months old WT, LCK-CD2-Tl1a Tg or FMS-Tl1a Tg mice are shown. (D) Masson Trichrome
staining of collagen deposition in tissue sections of mouse mid-colon. Collagen is stained blue versus red background. There are increased blue
collagen stain in LCK-CD2-Tl1a Tg and FMS-Tl1a Tg compared to WT littermate mice. Magnification 200X. Results are representative of six mice per
group for A–D.
doi:10.1371/journal.pone.0016090.g003
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PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e16090Figure 4. Constitutive Tl1a expression leads to increased numbers of goblet and Paneth cells in the small intestine and ileal
histological inflammation. (A) Representative H&E stained sections obtained from the indicated portions of small intestine from 2 months old WT,
LCK-CD2-Tl1a Tg (L-Tg)o rFMS-Tl1a Tg (M-Tg) mice are shown. Goblet cells are denoted by an open arrow. Paneth cells are denoted by a filled arrow.
Results are representative of six mice per group. Magnification 200X. (B) The numbers of goblet (top panel) and Paneth cells (middle panel) were
determined by examining at least 80 individual villi at the indicated portions of the small intestine from six mice (2 months old) per group by 2
observers blinded to mouse genotype. Data are expressed as mean (SD. Histologic scores (bottom panel) were determined by 2 observers blinded to
mice using standard methods [21]. Data are expressed as mean (SD. At least 36 fields from 6 mice per group at 200x magnification were scored.
*P,0.05, **P,0.01.
doi:10.1371/journal.pone.0016090.g004
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PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e16090Figure 5. Persistent Paneth cell hyperplasia and worsened small intestinal inflammation as the Tl1a Tg mice aged. (A) Representative
H&E stained section obtained from the indicated portions of small intestine from 10 months old WT, LCK-CD2-Tl1a Tg (L-Tg)o rFMS-Tl1a Tg (M-Tg)
mice are shown. Goblet cells are denoted by an open arrow. Paneth cells are denoted by a filled arrow. Results are representative of six mice per
group. Magnification 200X. (B) The numbers of goblet (top panel) and Paneth cells (middle panel) were determined by 2 observers blinded to mice
genotype. Histologic scores (bottom panel) were determined from 10 months old WT, LCK-CD2-Tl1a Tg (L-Tg), or FMS-Tl1a Tg (M-Tg) mice using
standard methods [21]. Quantification of goblet and Paneth cells was determined by examining at least 80 individual villi and histological scores were
determined by examining at least 36 fields at 200X magnification. Six independent mice per group were used (A–B). Data are expressed as mean (SD.
*P,0.05, **P,0.01.
doi:10.1371/journal.pone.0016090.g005
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PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e16090mice at 2 months and the difference became even greater as the
mice aged (Fig. 11A). For the FMS-Tl1a Tg mice, a higher
percentage of CCR9
+ and CCR10
+ cells was observed at 10
months (but not at 2 months) (Fig. 11A).
Tl1a Tg mice have an enhanced proinflammatory
cytokine profile in the MLN and small intestine
To assess the molecular consequences of increased expression of
activation and gut homing marker, we measured the expression of
IFN-c, IL-13 and IL-17 by FACS analysis and ELISA. There was







+ T cells by either intracellular stain or ELISA at 2
months of age between FMS-Tl1a Tg, LCK-CD2-Tl1a Tg or WT





+ T cells increased by
approximately 3- and 2- fold respectively, in the MLN of LCK-
CD2-Tl1a Tg mice (Fig. 11B). In the FMS-Tl1a Tg mice, the
percentage of CD4
+IFN-c
+ cells increased by approximately 2-fold
(Fig. 11B). We did not observe any differences in the CD4
+IL-13
+
T cells in both of the Tl1a Tg mice and only a negligible difference
in the CD4
+IL-17
+ T cells in FMS-Tl1a Tg mice (Fig. 11B).
To confirm the FACS findings, we isolated cells from the spleen,
MLN and LPMC from the colon and small intestine and assessed
their ability to produce cytokines following stimulation with anti-
CD3 and anti-CD28. Similar to the intracellular stain, we found
significantly higher IFN-c production in the MLN and small
intestine LPMC of LCK-CD2-Tl1a Tg mice (Fig. 12A). FMS-Tl1a
Tg mice also exhibited significantly increased IFN-c production in
MLN and a trend toward a higher level in the LPMC from the
small intestine (Fig. 12A). There was also a trend toward higher
IL-17 and IL-13 production in the MLN and small intestine
LPMC of both LCK-CD2-Tl1a and FMS-Tl1a Tg mice, but this did
not reach statistical significance (Fig. 12B and C). Interestingly, the
expression of the anti-inflammatory cytokine IL-10 appeared to be
higher in both the Tl1a Tg mice and reached statistical significance
in the splenic cells of LCK-CD2-Tl1a Tg as compared to WT mice
(Fig. 12D). These data suggested that constitutive expression of
Tl1a in vivo resulted in enhanced IFN-c and IL-10 production and
potentially enhanced IL-17 and IL-13 production.
Discussion
This study shows that constitutive expression of Tl1a on either
T- or APC cells leads to progressive histological inflammation in
the small intestine and worsened fibrosis in both the small intestine
and colon over time. Even though sustained expression of Tl1a in
T- or APC did not result in gross macroscopic gut inflammation or
colitis symptoms as measured by DAI (weight loss, fecal occult
blood or loose stool) for up to 1 year, there were histologically
determined inflammation as evidenced by blunting of the small
intestinal villi, hyperplasia of goblet and Paneth cells and increased
LPMC infiltrate. These histological changes are markers of early
gut inflammation that are also found in other murine models of
colitis and ileitis [25,26]. As the small bowel inflammation
worsened with age, there was no difference in the goblet cell
number between Tl1a Tg and WT littermate mice (Fig. 4 and 5).
This was likely due to the fact that goblet cell number decreased
with worsened inflammation in older Tl1a Tg mice [26,27,28].
This histologic inflammation was only detected in the small
intestine (not colon) and was particularly evident in the ileum. The
degree of inflammation in the small intestine was similar between
Tg mice with sustained Tl1a expression in T- and myeloid cells
(Fig. 4).
Figure 6. Increased fibrosis in the small intestine of Tl1a Tg mice. Masson Trichrome staining was performed on mice ileal sections (distal
3 cm of small intestine). There is increased blue collagen stain in LCK-CD2-Tl1a Tg and FMS-Tl1a Tg compared to WT littermate mice. Magnification
200X. Six independent mice per group were used.
doi:10.1371/journal.pone.0016090.g006
Figure 7. Tl1a transgenic mice develop ulcerated skin lesions
and arthropathy. A typical ulcerated skin lesion is illustrated (white
arrow, top). Erythematous arthropathy found in the transgenic (Tg) mice
is shown (black arrow, middle). A WT joint is shown in the bottom panel
for comparison.
doi:10.1371/journal.pone.0016090.g007
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PLoS ONE | www.plosone.org 8 January 2011 | Volume 6 | Issue 1 | e16090Another histological finding was increased small intestinal and
colonic fibrosis in Tl1a Tg compared to WT littermate mice by 10
months of age (Fig. 3D and 6). This could be due to the fact that
there was higher transgene expression in the LCK-CD2-Tl1a Tg
mouse (approximately 90% of T cells) compared to its expression
in APC (approximately 70% of DC and macrophages). Alterna-
tively, constitutive Tl1a expression in lymphocytes could be more
fibrogenic than its expression on either DC or macrophages. The
presence of colonic fibrosis in the absence of detectable histologic
inflammation suggested that Tl1a may be a pro-fibrogenic factor
in addition to its role in inflammation. Notably, TL1A haplotype B
which is associated with increased secretion of soluble and
Figure 8. Sustained Tl1a expression leads to an increased percentage of activated T cells. FACS plot of 2 month (A) and 10 month (B)
splenocytes and MLN cells showing expression of activation markers CD44. Either CD4
+ or CD8
+ cells are gated as indicated. Data shown are
representative of 4 mice per group. WT = wildtype, L-Tg = LCK-CD2-Tl1a-GFP Tg mice, M-Tg = FMS-Tl1a Tg mice.
doi:10.1371/journal.pone.0016090.g008
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PLoS ONE | www.plosone.org 9 January 2011 | Volume 6 | Issue 1 | e16090membrane TL1A is also characterized by increased need for
surgery especially in Jewish patients [23,24]. Fibrostenotic disease
was also more common in this group. It would be medically useful
to determine whether downregulating the TL1A/DR3 pathway
can prevent the progression of IBD-associated fibrosis since there
is currently no effective medical therapy to treat established
fibrostenotic disease in IBD patients. It would be interesting to
study the interaction between TL1A and other known pro-
fibrogenic factors such as transforming growth factor beta 1 (TGF-
b1) and insulin-like growth factor 1 (IGF-1) using the chronic
2,4,6-trinitrobenzensulfonic acid (TNBS) colonic injury model
which causes both colitis and intestinal fibrosis [29,30,31].
Figure 9. Sustained Tl1a expression leads to an increased percentage of activated DC and macrophages. FACS plot of 2 month (A) and
10 month (B) splenocytes and MLN cells showing expression of activation markers CD86. Either F4/80
+ or CD11c
+ cells were gated as indicated. Data
shown are representative of 4 mice per group. WT = wildtype, L-Tg = LCK-CD2-Tl1a-GFP Tg mice, M-Tg = FMS-Tl1a Tg mice.
doi:10.1371/journal.pone.0016090.g009
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PLoS ONE | www.plosone.org 10 January 2011 | Volume 6 | Issue 1 | e16090We observed a low frequency of extra-intestinal pathology in
both LCK-CD2-Tl1a Tg and FMS-Tl1a Tg mice. These included
ulcerated skin lesions and erythematous swollen joints (fig. 7),
which are similar to known extra-intestinal manifestations
associated with human IBD. The cause of the extra-intestinal
pathology in Tl1a Tg mice remains to be investigated, but may be
related to the differential expression of CCR10 homing molecules
in the Tl1a Tg mice. In addition to its function as a gut mucosal
homing receptor [32], CCR10 is important in lymphocyte
trafficking to the skin [33,34].
The chemokine receptors CCR9 and CCR10 play a major role
in in vivo lymphocyte trafficking to portals of microbial entry, such
as gut mucosal tissues and the skin [33,34,35,36,37]. The higher
LPMC infiltrate in the small intestine as compared to the colon in
Tl1a Tg mice may be due to the fact that CCR9 is preferentially
found in the small intestine [38] and its ligand CCL25/TECK is
expressed in both lamina propria venules and small intestine
enterocytes [39,40]. In contrast, colonic expression of CCR9 and
its ligand CCL25/TECK is limited [39,40]. The clinical
importance of dysregulated immune trafficking in IBD is
highlighted by the efficacious therapies such as natalizumab that
blocks gut homing in inducing and maintaining remission in CD
[41].
We found that constitutive expression of Tl1a resulted in a
progressive activated phenotype over time in CD4
+ and CD8
+ T
cells (Fig. 8), macrophages and DC (Fig. 9). Increased T cell and
APC activation in Tl1a Tg mice may be a direct consequence of
constitutive TL1a costimulation of DR3 expressing T cells and
macrophages [11,42,43] or indirectly through failure of immuno-
logical tolerance leading to enhanced activation. In fact, recent
studies have shown that the TL1A-DR3 pathway can attenuate
the suppressive effect of Tregs on effector T cells [16,17]. The
activated phenotype of T and APC in combination with the
constitutive costimulation of TL1A-DR3 signaling pathway may
lead to the significantly higher IFN-c expression (Fig. 11B and
12A) that we saw in the Tl1a Tg mice, which is consistent with the
previous observation that TL1A is involved in mediating the Th1
response [4,5,8,9,13,14,15,44,45]. There was also a trend toward
increased IL-13 and IL-17 expression in mice with constitutive
Tl1a expression (Fig. 12B and C), which was consistent with the
Figure 10. Increased numbers of regulatory T (Treg) cells in Tl1a Tg mice. FACS plot of CD4
+ Foxp3
+ splenocytes (A) or CD4
+ Foxp3
+ MLN
cells (B) are shown. Data shown are representative of 4 mice per group at either 2 or 10 months of age. WT = wildtype, L-Tg = LCK-CD2-Tl1a-GFP Tg
mice, M-Tg = FMS-Tl1a-GFP Tg mice.
doi:10.1371/journal.pone.0016090.g010
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mouse models [9,10,11,12,16,17]. Lastly, we found significantly
increased IL-10 production in LCK-CD2-Tl1a Tg mice (Fig. 12D),
which could be related to higher percentage of Foxp3
+ Treg cells
in LCK-CD2-Tl1a Tg as compared to FMS-Tl1a Tg or WT mice
(Fig. 10A and B).
Recently, two groups independently reported the generation of
transgenic mice with sustained TL1A expression in DC and T
cells. Our results were similar to the constitutive Tl1a expressing
Tg mice in Meylan et al. and Taraban et al., with the increased
goblet, Paneth and Treg cells, ileitis and activated phenotype in T
and APC cells [16,17]. However, a major difference was that the
Figure 12. Cytokine profile of Tl1a Tg and WT littermate mice. IFN-c (A), IL-17 (B), IL-13 (C) and IL-10 (D) secretion after stimulation with anti-
CD3 and anti-CD28 were assessed by enzyme-linked immunosorbent assay (ELISA). Each data point (A-D) represents cytokine expression for either
splenocytes, MLN cells or lamina propria mononuclear cells (LPMC) from either the colon or the distal 10 cm of small intestine isolated from an
individual mouse. p-values are indicated the figure where significant. WT = wildtype, L-Tg = LCK-CD2-Tl1a-GFP Tg mice, M-Tg = FMS-Tl1a Tg mice.
doi:10.1371/journal.pone.0016090.g012
Figure 11. Increased expression of gut homing markers and IFN-c in Tl1a Tg mice. (A) FACS plots showing expression of gut homing
markers CCR9 and CCR10 on CD4
+ cells isolated from the MLN. (B) FACS plot of gated CD4
+ cells from MLN and stained for intracellular IFN-c, IL-17,
and IL-13 expression from 10 months old WT, LCK-CD2-Tl1a Tg (L-Tg)o rFMS-Tl1a Tg (M-Tg) mice. Data shown are representative of 4 mice per group
(A and B). Black bars indicate area under the curve that is gated as CCR9 positive cells. WT = wildtype, L-Tg = LCK-CD2-Tl1a-GFP Tg mice, M-Tg =
FMS-Tl1a Tg mice.
doi:10.1371/journal.pone.0016090.g011
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mainly attributed to Th2/IL-13 effector pathway [16,17], whereas
we observed a higher production of IFN-c from the Tl1a Tg mice
generated in this study (Fig. 11B and 12A). In addition, we
observed extra-intestinal pathology and increased gut fibrosis in
the Tl1a Tg mice, which were not reported in the other Tl1a Tg
mice. Several reasons may account for the phenotypical
differences between the Tl1a Tg mice. One explanation may be
methodological differences. For example, different promoter/
enhancer elements were used to drive tissue specific expression of
the different Tl1a Tg mice. We used the LCK-CD2 promoter/
enhancer element [19], whereas the CD2 promoter [46] was used
to generate the T cell specific Tl1a Tg mice [16]. The c-fms
promoter vector [18] was used to generate myeloid specific Tl1a
Tg mice for this report whereas the CD11c promoter [47] was used
for the recently published studies [16,17]. Differences in the
phenotype of the transgenic mice using the different T cell
promoter/enhancer element to drive transgene expression was
observed previously in the T cell specific LIGHT Tg mice
[19,48,49]. Another reason may lie in the mouse strain used.
The Tl1a Tg mice used in this report were generated by direct
microinjection into C57BL/6 pronuclei whereas the DC specific
Tl1a Tg mouse [17] was generated by microinjecting into FVB/N
zygotes and subsequently backcrossed 4–5 generations to the
C57BL/6 strain. Alternatively, these phenotypical differences may
be due to the different gut microflora between the animal housing
facilities. Previous studies have demonstrated that genetically
identical inbred mice strain raised in different facilities had
different immune composition due to the different intestinal
microbiota composition [50,51,52]. The potential immunomodu-
latory role of gut microbiota in the different Tl1a Tg mice
highlights the previously described role of the TL1A-DR3
signaling pathway in bacteria recognition and microbial-host
interactions [6,8,10,16].
In summary, we generated tissue specific, in vivo expression of
Tl1a in T cells and APC and found that it lead to patchy small
bowel inflammation and fibrosis in both the small intestine and the
colon. Sustained expression of Tl1a leads to an activated immune
phenotype, increased expression of gut homing molecules and Th1
(and possibly Th17 and Th2) responses. These novel Tl1a
transgenic models of intestinal inflammation may be useful to
study fibrotic response in inflammation and the pathogenesis of
various disorders of immune dysregulation such as IBD.
Materials and Methods
Transgenic mice and genotype
Murine Tl1A cDNA (Open Biosystems, Clone ID 30740802)
was digested by EcoRI/SmaI and inserted into the EcoRI/SmaI
site of pIRES2-EGFP (Clontech). To generate lymphoid specific
Tl1A transgenic mice, DNA fragment containing murine Tl1A-
IRES2-EGFP was amplified by PCR using sense primer 59-
AATGGGGGCGCGCCGGGCTCTCTGGTCAGAAGGGAT-
CAG-39 and antisense primer 59-TTTACGGGCGCGCCCCT-
TAAGATACATTGATGAGTTTGG-39, digested with AscI, and
cloned into AscI site of plck.E2 (generous gift from T. Hettmann,
The University of Chicago), which contains the proximal lck
promoter, human growth hormone gene (polyadenylation site),
and locus control region elements from the human CD2 gene to
generate plasmid pLCK-Tl1a-IRES2-EGFP. The plck.E2 has
been used to mediate T cell lineage specific expression [19]. The
Tl1A-IRES2-EGFP fragment was sequenced to confirm that no
mutations were generated during the cloning process. A 10-kb
fragment was excised by NotI digest and used for microinjection
into C57BL/6 pronuclei performed by Caliper Life Sciences. 8
independent murine lines containing genomic integration of the
Tl1a transgene were identified by PCR using the following primers:
59- GACTAACAAAGATGCCTGCCTGTGG-39 and 59-GC-
CATCCTTCTGCTGTCTTGGAGA-39. Only 2 of the 8 lines
showed T-cell lineage specific expression of TL1A (95% of T cells
and 34% of T cells). We used the founder transgenic (Tg) mouse
line with Tl1A transgene expression in 95% of T cells and called it
LCK-CD2-Tl1A-GFP Tg mouse.
To generate myeloid specific Tl1a Tg mice, a XhoI/EcoRI
fragment was blunt ended by klenow (NEB) and cloned to blunt
ended MluI site of c-fms promoter vector (generous gift from D.
Underhill, Cedars-Sinai Medical Center). Tl1A-IRES2-EGFP
fragment was sequenced to confirm that no mutations were
generated during the cloning process. The c-fms promoter vector
has been used previously to drive expression for cells of the
mononuclear phagocyte lineage including macrophages and
dendritic cells [18]. A 10-kb fragment was excised by XhoI/ClaI
digest and used for microinjection into C57BL/6 pronuclei
performed by Caliper Life Sciences. 6 independent murine lines
containing genomic integration of the Tl1a transgene were
identified by PCR using the following primers: 59-TTG-
GAAGCTGATTGAAGGGTCCA-39 and 59-AGCTCCTC-
TGCCATCCTTCTGCT-39. Two of the six lines showed
myeloid specific expression of the transgene in approximately
70% of macrophages and dendritic cells, but one has higher GFP
level than the other founder line. We used the founder Tg line with
the higher GFP expression and called this line FMS-Tl1a-GFP Tg
mouse.
All mice were maintained under specific pathogen-free
conditions in the Animal Care Facility at Cedars-Sinai Medical
Center. Littermate control mice were used for all experiments.
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the NIH. Mice used in all experiments
were specifically approved by Cedars-Sinai Medical Center
Animal Care and Use Committee. Approved protocol 2269 was
used for this study.
Disease activity index (DAI), macroscopic and
histopathological analysis
Mice were weighed and inspected for diarrhea and rectal
bleeding once a week for the first 2 months after weaning, then
once a month thereafter. The DAI (combined score of weight loss,
presence of blood in stool, and stool consistency) was determined
according to a standard scoring system previously described [20].
Colon and small intestine were scored for macroscopic evidence of
inflammation using the established classification [21]. Tissue was
fixed in 10% neutral buffered formalin (Sigma). Samples were
embedded, sectioned, and stained with hematoxylin and eosin by
the Histology Core at Cedars-Sinai Medical Center. Masson
Trichrome staining was performed as described previously [29].
Histopathological scores of colons and small intestine were
assigned in a blinded manner by at least 2 trained pathologists
(DQS and HWK) using previously established methods [21]. The
histologic score is calculated from observation of at least 36
different fields of stained sections at 200X from 6 mice in each
group. The numbers of goblet cells and Paneth cells were
determined by examining at least 80 individual villi and crypts
from each group.
Real-time PCR analysis
Total RNA was isolated as previously described [8]. Two
micrograms of total RNA was used in each RT reaction using the
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actin transcripts were amplified by quantitative real-time RT-PCR
as previously described [9]. Duplicates differing by less than one
cycle were averaged and amount of transcript was analyzed and
expressed as percentage of b-actin.
Cell isolation and culture
LPMC isolation, culture, and stimulation by anti-CD28 and
anti-CD3[ were carried out as previously reported [9]. We used
the whole colon for LPMC isolation. We used the distal 10 cm of
the SB for LPMC isolation. Cytokine concentration was assayed
by enzyme-linked immunosorbent assay (ELISA) using ELISA kits
for IFN-c, IL-17 IL-13, and IL-10 (eBioscience) per manufacture
protocol and as previously described [9].
Flow cytometry and measurement of intracellular
cytokine expression
Cells were stained with antibodies against murine CD4 (RM4-
5), CD44 (IM7), CD86 (GL1) (BD Biosciences), CCR9 (242503),
CCR10 (248918) (R&D systems), CD8 (53-6.7), CD11c (N418),
F4/80 (BM8) (Biolegend) and FoxP3 (FJK-165) (eBiosciences).
CD16/CD32 (clone 2.4G2) was used to block nonspecific FcR
binding (eBiosciences). Intracellular staining was performed with
antibodies against IFN-c (XMG1.2), IL-17 (17B7) and IL13 (13a)
(eBioSciences). For determination of intracellular cytokine pro-
duction by leukocytes, cells were incubated for 5 hours at 37uC
with BD Leukocyte Activation Cocktail with BD GolgiPlug (BD
Biosciences). For FoxP3 staining, fixation and permeabilization
buffers provided from the manufacturer (eBiosciences) were used.
Data of the stained cells were acquired on a Cyan flow cytometer
(Dako-Cytomation) and analyzed using FlowJo analysis software
(Tree Star, Inc).
Statistical analysis
Data are presented as the mean 6 standard deviation.
Comparison between two groups was performed by a two tailed,
Student’s t-test. A value of p,0.05 was considered significant.
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